Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04165512
Other study ID # 09.2019.984
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date January 7, 2020
Est. completion date April 2020

Study information

Verified date January 2020
Source Marmara University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lymphedema is a condition characterized by generalized or regional accumulation of protein-rich interstitial fluid as a result of impaired lymphatic circulation due to congenital or acquired disorders. Lymphedema is diagnosed through evaluations of its clinical criteria. Lymphedema is mostly evaluated through arm circumference measurements, water displacement measurements, tonometry, bioimpedance analysis, ultrasonography (US), computed tomography, lymphoscintigraphy and magnetic resonance imaging (MRI). Targets in the treatment of lymphedema include controlling the symptoms and preventing complications. A multimodal technique called complete decongestive therapy (CDT) is considered the gold standard of the treatment of lymphedema. In the literature, there are also studies showing that stellate ganglion block in breast cancer-related lymphedema treatment improves lymphedema and symptoms. Cervical stellate ganglion block is an invasive method used for the diagnosis and treatment of sympathetic pain and symptoms of upper extremity. Although it can be performed with fluoroscopy, CT and MRI, there has been increasing interest in ultrasound-guided technique since it has been fast, easy and cost-effective for the last few years. However, there are limited studies to provide sufficient evidence for the use of stellate ganglion block as an alternative treatment for lymphedema and detailed studies are needed in this area. The aim of this study is ultrasonographic evaluation of the efficacy of stellate ganglion block in the treatment of patients with breast cancer related lymphedema that is resistant to conservative treatment methods .


Description:

Lymphedema is a condition characterized by generalized or regional accumulation of protein-rich interstitial fluid as a result of impaired lymphatic circulation due to congenital or acquired disorders. Lymphedema is diagnosed through evaluations of its clinical criteria. In addition to swelling of the affected extremities, certain symptoms, such as pain, fatigue, tightness, heaviness, tingling, weakness, and movement restriction, can also be seen in cases of lymphedema. Arm circumference measurements and volumetric methods are the most commonly used methods for calculating limb volume. In addition, soft tissue edema can be quantitatively measured by ultrasonography (US), computed tomography, lymphoscintigraphy and magnetic resonance imaging (MRI). Among these, US has been used more frequently in the evaluation of lymphedema. Ultrasonographic evaluation of the skin and subcutaneous tissue helps to determine the severity of lymphedema and the effectiveness of treatment. The reliability and utility of ultrasound in subcutaneous echogenicity grade (SEG) and subcutaneous echo-free space (SEFS) grade have been demonstrated in patients with breast cancer-related lymphedema. Targets in the treatment of lymphedema include controlling the symptoms and preventing complications. A multimodal technique called complete decongestive therapy (CDT) is considered the gold standard of the treatment of lymphedema. In the literature, there are also studies showing that stellate ganglion block in breast cancer-related lymphedema treatment improves lymphedema and symptoms. Cervical stellate ganglion block is an invasive method used for the diagnosis and treatment of sympathetic pain and symptoms of upper extremity. Although it can be performed with fluoroscopy, CT and MRI, there has been increasing interest in ultrasound-guided technique since it has been fast, easy and cost-effective for the last few years. However, there are limited studies to provide sufficient evidence for the use of stellate ganglion block as an alternative treatment for lymphedema and detailed studies are needed in this area. The aim of this study is ultrasonographic evaluation of the efficacy of stellate ganglion block in the treatment of patients with breast cancer related lymphedema that is resistant to conservative treatment methods.

Patients with breast cancer-related lymphedema will be evaluated for the study. For the diagnosis of lymphedema, detailed physical examination and limb circumference measurements will be performed. The patients with stage 2-3 lymphedema according to ISL staging, who had passed at least 3 months after breast surgery and did not response to conservative treatment methods will be included to the study. After obtaining written and oral informed consent of patients, US- guided stellate ganglion block will be applied two times at two-week intervals. Patients will be evaluated before injections (weeks 0 and 2) and 2 weeks after the last injection (week 4) and at 3 months of treatment. Arm circumference will be measured from 5 different areas, shoulder range of motion (ROM) will be evaluated with a goniometer, pain, and tightness and heaviness sensation will be assessed with visual analog scale. Quick-DASH questionnaire and Lymphedema Life Impcat scale will be applied to the patients. SEG and SEFS grade will be performed by evaluating subcutaneous tissue with USG.

After data collection, analysis will be performed with the appropriate statistical method.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 22
Est. completion date April 2020
Est. primary completion date March 2020
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- circumference difference of 2 cm or more between the affected and unaffected arm

- stage 2-3 lymphedema according to ISL staging

- aged between 18-70 years

- at least 3 months of follow-up breast surgery

- no response to the complete decongestive therapy enough

Exclusion Criteria:

- signs of cellulitis, lymphangitis, fungal infection,

- metastases to the lymph nodes

- uncontrolled psychiatric and systemic diseases

- contraindications for stellate ganglion block

Study Design


Intervention

Combination Product:
bupivacaine and triamcinolone
a mixture of 4 mL 0.5% bupivacaine (marcaine) and 1 mL 40 mg triamcinolone (kenacort-a)

Locations

Country Name City State
Turkey Canan Sanal-Toprak Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Marmara University

Country where clinical trial is conducted

Turkey, 

References & Publications (5)

Kim J, Park HS, Cho SY, Baik HJ, Kim JH. The effect of stellate ganglion block on intractable lymphedema after breast cancer surgery. Korean J Pain. 2015 Jan;28(1):61-3. doi: 10.3344/kjp.2015.28.1.61. Epub 2015 Jan 2. — View Citation

Kim JG, Bae SO, Seo KS. A comparison of the effectiveness of complex decongestive physiotherapy and stellate ganglion block with triamcinolone administration in breast cancer-related lymphedema patients. Support Care Cancer. 2015 Aug;23(8):2305-10. doi: 10.1007/s00520-014-2593-5. Epub 2015 Jan 11. — View Citation

Park JH, Min YS, Chun SM, Seo KS. Effects of stellate ganglion block on breast cancer-related lymphedema: comparison of various injectates. Pain Physician. 2015 Jan-Feb;18(1):93-9. — View Citation

Park MW, Lee SU, Kwon S, Seo KS. Comparison Between the Effectiveness of Complex Decongestive Therapy and Stellate Ganglion Block in Patients with Breast Cancer-Related Lymphedema: A Randomized Controlled Study. Pain Physician. 2019 May;22(3):255-263. — View Citation

Suehiro K, Morikage N, Yamashita O, Harada T, Samura M, Takeuchi Y, Mizoguchi T, Nakamura K, Hamano K. Skin and Subcutaneous Tissue Ultrasonography Features in Breast Cancer-Related Lymphedema. Ann Vasc Dis. 2016;9(4):312-316. doi: 10.3400/avd.oa.16-00086. Epub 2016 Nov 25. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Arm circumference difference Circumference differences between the affected and unaffected arms will be measured with a nonelastic tape measure at five levels; metacarpophalangeal joints, wrist, 15 cm distally from the medial epicondyle, medial epicondyle and 15 cm proximally from the medial epicondyle upper extremities. before treatment (T0)
Primary Arm circumference difference Circumference differences between the affected and unaffected arms will be measured with a nonelastic tape measure at five levels; metacarpophalangeal joints, wrist, 15 cm distally from the medial epicondyle, medial epicondyle and 15 cm proximally from the medial epicondyle upper extremities. 2nd week of treatment (T1)
Primary Arm circumference difference Circumference differences between the affected and unaffected arms will be measured with a nonelastic tape measure at five levels; metacarpophalangeal joints, wrist, 15 cm distally from the medial epicondyle, medial epicondyle and 15 cm proximally from the medial epicondyle upper extremities. 4th week of treatment (T2)
Primary Arm circumference difference Circumference differences between the affected and unaffected arms will be measured with a nonelastic tape measure at five levels; metacarpophalangeal joints, wrist, 15 cm distally from the medial epicondyle, medial epicondyle and 15 cm proximally from the medial epicondyle upper extremities. 3rd month of treatment (T3)
Primary Subcutaneous echogenicity grade (SEG) SEG will be performed by evaluating subcutaneous tissue with USG. Grade 0: No or little increase in echogenicity. Grade 1: Grade 1: Diffuse and monotonous increases in echogenicity Grade 2: Diffuse increases in echogenicity before treatment (T0)
Primary Subcutaneous echogenicity grade (SEG) SEG will be performed by evaluating subcutaneous tissue with USG. Grade 0: No or little increase in echogenicity. Grade 1: Grade 1: Diffuse and monotonous increases in echogenicity Grade 2: Diffuse increases in echogenicity 2nd week of treatment (T1)
Primary Subcutaneous echogenicity grade (SEG) SEG will be performed by evaluating subcutaneous tissue with USG. Grade 0: No or little increase in echogenicity. Grade 1: Grade 1: Diffuse and monotonous increases in echogenicity Grade 2: Diffuse increases in echogenicity 4th week of treatment (T2)
Primary Subcutaneous echogenicity grade (SEG) SEG will be performed by evaluating subcutaneous tissue with USG. Grade 0: No or little increase in echogenicity. Grade 1: Grade 1: Diffuse and monotonous increases in echogenicity Grade 2: Diffuse increases in echogenicity 3rd month of treatment (T3)
Primary Subcutaneous echo-free space (SEFS) grade SEFS grade will be performed by evaluating subcutaneous tissue with USG. Grade 0: No SEFS. Grade 1: Horizontally oriented (<45 degrees to the skin) SEFS only. Grade 2: Presence of vertically oriented (=45 degrees to the skin) SEFS bridging the horizontally oriented SEFSs. before treatment (T0)
Primary Subcutaneous echo-free space (SEFS) grade SEFS grade will be performed by evaluating subcutaneous tissue with USG. Grade 0: No SEFS. Grade 1: Horizontally oriented (<45 degrees to the skin) SEFS only. Grade 2: Presence of vertically oriented (=45 degrees to the skin) SEFS bridging the horizontally oriented SEFSs. 2nd week of treatment (T1)
Primary Subcutaneous echo-free space (SEFS) grade SEFS grade will be performed by evaluating subcutaneous tissue with USG. Grade 0: No SEFS. Grade 1: Horizontally oriented (<45 degrees to the skin) SEFS only. Grade 2: Presence of vertically oriented (=45 degrees to the skin) SEFS bridging the horizontally oriented SEFSs. 4th week of treatment (T2)
Primary Subcutaneous echo-free space (SEFS) grade SEFS grade will be performed by evaluating subcutaneous tissue with USG. Grade 0: No SEFS. Grade 1: Horizontally oriented (<45 degrees to the skin) SEFS only. Grade 2: Presence of vertically oriented (=45 degrees to the skin) SEFS bridging the horizontally oriented SEFSs. 3rd month of treatment (T3)
Primary shoulder range of motion (ROM) will be evaluated with a goniometer Shoulder range of motion (ROM) will be evaluated with a goniometer in all directions; flexion, extension, abduction, adduction, internal and external rotation. before treatment (T0)
Primary shoulder range of motion (ROM) will be evaluated with a goniometer Shoulder range of motion (ROM) will be evaluated with a goniometer in all directions; flexion, extension, abduction, adduction, internal and external rotation. 2nd week of treatment (T1)
Primary shoulder range of motion (ROM) will be evaluated with a goniometer Shoulder range of motion (ROM) will be evaluated with a goniometer in all directions; flexion, extension, abduction, adduction, internal and external rotation. 4th week of treatment (T2)
Primary shoulder range of motion (ROM) will be evaluated with a goniometer Shoulder range of motion (ROM) will be evaluated with a goniometer in all directions; flexion, extension, abduction, adduction, internal and external rotation. 3rd month of treatment (T3)
Primary Pain, tightness and heaviness sensation Shoulder pain and sensations of tightness and heaviness will be evaluated with a 10-cm horizontal visual analogue scale (VAS) ranging from "0 cm" (no discomfort) to "10 cm" (worst imaginable) before treatment (T0)
Primary Pain, tightness and heaviness sensation Shoulder pain and sensations of tightness and heaviness will be evaluated with a 10-cm horizontal visual analogue scale (VAS) ranging from "0 cm" (no discomfort) to "10 cm" (worst imaginable) 2nd week of treatment (T1)
Primary Pain, tightness and heaviness sensation Shoulder pain and sensations of tightness and heaviness will be evaluated with a 10-cm horizontal visual analogue scale (VAS) ranging from "0 cm" (no discomfort) to "10 cm" (worst imaginable) 4th week of treatment (T2)
Primary Pain, tightness and heaviness sensation Shoulder pain and sensations of tightness and heaviness will be evaluated with a 10-cm horizontal visual analogue scale (VAS) ranging from "0 cm" (no discomfort) to "10 cm" (worst imaginable) 3rd month of treatment (T3)
Secondary Activity and participation - Quick-DASH Quick-DASH is an assessment questionnaire that measures activity and participation limitations in all upper extremity disorders. The questionnaire assesses the difficulty of the daily life activities of the patients with 11 questions. Each answer is scored from 1 to 5 with a Likert scale. There is also two optional 4-item additional modules for whose jobs require a lot of upper limb performance and for sports people and musicians. The validity and reliability of the questionnaire in Turkish were conducted by Düger et al. before treatment (T0)
Secondary Activity and participation - Quick-DASH Quick-DASH is an assessment questionnaire that measures activity and participation limitations in all upper extremity disorders. The questionnaire assesses the difficulty of the daily life activities of the patients with 11 questions. Each answer is scored from 1 to 5 with a Likert scale. There is also two optional 4-item additional modules for whose jobs require a lot of upper limb performance and for sports people and musicians. The validity and reliability of the questionnaire in Turkish were conducted by Düger et al. 2nd week of treatment (T1)
Secondary Activity and participation - Quick-DASH Quick-DASH is an assessment questionnaire that measures activity and participation limitations in all upper extremity disorders. The questionnaire assesses the difficulty of the daily life activities of the patients with 11 questions. Each answer is scored from 1 to 5 with a Likert scale. There is also two optional 4-item additional modules for whose jobs require a lot of upper limb performance and for sports people and musicians. The validity and reliability of the questionnaire in Turkish were conducted by Düger et al. 4th week of treatment (T2)
Secondary Activity and participation - Quick-DASH Quick-DASH is an assessment questionnaire that measures activity and participation limitations in all upper extremity disorders. The questionnaire assesses the difficulty of the daily life activities of the patients with 11 questions. Each answer is scored from 1 to 5 with a Likert scale. There is also two optional 4-item additional modules for whose jobs require a lot of upper limb performance and for sports people and musicians. The validity and reliability of the questionnaire in Turkish were conducted by Düger et al. 3rd month of treatment (T3)
Secondary Quality of life - Lymphedema Life Impact Scale Lymphedema Life Impact Scale is a questionnaire developed to evaluate the physical, functional and psychosocial effects of lymphedema. It consists of 18 questions; It includes 8 physical, 4 psychosocial and 6 function subgroups. Each question is scored between 1 and 5, and high scores indicate increased severity. The validity and reliability of the Turkish version was made by Degirmenci et al. before treatment (T0)
Secondary Quality of life - Lymphedema Life Impact Scale Lymphedema Life Impact Scale is a questionnaire developed to evaluate the physical, functional and psychosocial effects of lymphedema. It consists of 18 questions; It includes 8 physical, 4 psychosocial and 6 function subgroups. Each question is scored between 1 and 5, and high scores indicate increased severity. The validity and reliability of the Turkish version was made by Degirmenci et al. 2nd week of treatment (T1)
Secondary Quality of life - Lymphedema Life Impact Scale Lymphedema Life Impact Scale is a questionnaire developed to evaluate the physical, functional and psychosocial effects of lymphedema. It consists of 18 questions; It includes 8 physical, 4 psychosocial and 6 function subgroups. Each question is scored between 1 and 5, and high scores indicate increased severity. The validity and reliability of the Turkish version was made by Degirmenci et al. 4th week of treatment (T2)
Secondary Quality of life - Lymphedema Life Impact Scale Lymphedema Life Impact Scale is a questionnaire developed to evaluate the physical, functional and psychosocial effects of lymphedema. It consists of 18 questions; It includes 8 physical, 4 psychosocial and 6 function subgroups. Each question is scored between 1 and 5, and high scores indicate increased severity. The validity and reliability of the Turkish version was made by Degirmenci et al. 3rd month of treatment (T3)
See also
  Status Clinical Trial Phase
Terminated NCT04858230 - LymphoPilot Test for Limb Lymphedema N/A
Completed NCT04575636 - MRL in the Upper Extremity N/A
Completed NCT03252145 - Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device N/A
Active, not recruiting NCT05441943 - Lymphaticovenous Anastomosis as Treatment for Lymphedema N/A
Completed NCT05754346 - Does Inclusion of Diaphragmatic Breathing Exercises in Complete Decongestive Therapy Provide Further Benefits in Patients With Breast Cancer Related Lymphedema N/A
Completed NCT06399458 - The Relationship Between Primary Lymphedema and Joint Hypermobility
Not yet recruiting NCT06264817 - Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema. N/A
Recruiting NCT06302361 - Lymphovenous Anastomosis for Breast Cancer Lymphedema N/A
Active, not recruiting NCT06278298 - Different Level of ECSWT in Post Mastectomy Lymphedema N/A
Completed NCT05037708 - Effects of Physiotherapy in the Treatment of Lymphedema After Breast Cancer N/A
Not yet recruiting NCT02453295 - Testing an Intervention to Foster Hope for Cancer Survivors With Lymphedema N/A
Completed NCT05660590 - Effect of Different Bandage Interface Pressures on Breast Cancer Related Lymphedema N/A
Withdrawn NCT02458391 - Complete Decongestive Therapy in Breast Cancer-Related Lymphedema N/A
Completed NCT04766489 - Evaluation of the Treatment Response in Breast Cancer Related Lymphedema N/A
Recruiting NCT05762224 - Comparative Effects of KT and PG on UE Lymphedema and Functional Disability After Mastectomy N/A
Recruiting NCT06082349 - The N-LVA Study: RCT Comparing LVA vs. Sham Surgery in Cancer-related Lymphedema N/A
Recruiting NCT05142800 - Screening For BCRL In Targeted Therapy For Breast Cancer
Recruiting NCT06012786 - Myofascial Pain Syndrome in Patients With Breast Cancer-related Lymphedema
Not yet recruiting NCT06113627 - Lymphatic Response to Resistance Exercise in Breast Cancer Survivors N/A
Completed NCT06036173 - Body Awareness and Functionality in Lymphedema